Raymond James & Associates Acquires Shares of 24,080 Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Raymond James & Associates acquired a new stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 24,080 shares of the biopharmaceutical company’s stock, valued at approximately $302,000.

Several other institutional investors also recently bought and sold shares of FOLD. Allspring Global Investments Holdings LLC grew its stake in shares of Amicus Therapeutics by 257.4% during the 2nd quarter. Allspring Global Investments Holdings LLC now owns 108,089 shares of the biopharmaceutical company’s stock worth $1,358,000 after purchasing an additional 77,844 shares during the period. Rice Hall James & Associates LLC grew its stake in shares of Amicus Therapeutics by 23.8% during the 2nd quarter. Rice Hall James & Associates LLC now owns 1,048,663 shares of the biopharmaceutical company’s stock worth $13,171,000 after purchasing an additional 201,804 shares during the period. Creative Planning acquired a new position in shares of Amicus Therapeutics during the 2nd quarter worth $176,000. Exchange Traded Concepts LLC acquired a new position in shares of Amicus Therapeutics during the 2nd quarter worth $77,000. Finally, Transcend Capital Advisors LLC grew its stake in shares of Amicus Therapeutics by 32.2% during the 2nd quarter. Transcend Capital Advisors LLC now owns 286,145 shares of the biopharmaceutical company’s stock worth $3,594,000 after purchasing an additional 69,686 shares during the period.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the stock. JPMorgan Chase & Co. boosted their price objective on shares of Amicus Therapeutics from $17.00 to $19.00 and gave the stock an “overweight” rating in a research report on Friday, September 29th. Bank of America boosted their price objective on shares of Amicus Therapeutics from $16.00 to $19.00 in a research report on Friday, September 29th. Morgan Stanley boosted their price objective on shares of Amicus Therapeutics from $14.00 to $15.00 and gave the stock an “equal weight” rating in a research report on Thursday. Finally, StockNews.com assumed coverage on shares of Amicus Therapeutics in a research report on Thursday, October 5th. They issued a “hold” rating on the stock. Three analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $16.17.

Insider Activity

In other news, Chairman John F. Crowley sold 6,044 shares of the company’s stock in a transaction dated Friday, September 1st. The shares were sold at an average price of $12.98, for a total transaction of $78,451.12. Following the completion of the transaction, the chairman now owns 920,053 shares of the company’s stock, valued at approximately $11,942,287.94. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. In related news, CEO Bradley L. Campbell sold 11,700 shares of the stock in a transaction that occurred on Wednesday, November 1st. The shares were sold at an average price of $10.97, for a total transaction of $128,349.00. Following the completion of the sale, the chief executive officer now owns 792,161 shares of the company’s stock, valued at approximately $8,690,006.17. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Chairman John F. Crowley sold 6,044 shares of the stock in a transaction that occurred on Friday, September 1st. The stock was sold at an average price of $12.98, for a total transaction of $78,451.12. Following the sale, the chairman now directly owns 920,053 shares of the company’s stock, valued at approximately $11,942,287.94. The disclosure for this sale can be found here. Insiders sold a total of 77,757 shares of company stock valued at $928,422 in the last 90 days. 2.10% of the stock is currently owned by insiders.

Amicus Therapeutics Price Performance

NASDAQ:FOLD opened at $10.41 on Friday. The firm has a market cap of $2.99 billion, a price-to-earnings ratio of -17.64 and a beta of 0.87. The company has a current ratio of 2.73, a quick ratio of 2.40 and a debt-to-equity ratio of 2.96. The company’s 50-day moving average is $11.57 and its two-hundred day moving average is $12.18. Amicus Therapeutics, Inc. has a 12-month low of $9.70 and a 12-month high of $14.10.

Amicus Therapeutics (NASDAQ:FOLD) last released its earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.01. The company had revenue of $103.50 million for the quarter, compared to analyst estimates of $102.30 million. Amicus Therapeutics had a negative net margin of 46.61% and a negative return on equity of 147.61%. The firm’s quarterly revenue was up 26.7% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.12) EPS. Research analysts expect that Amicus Therapeutics, Inc. will post -0.44 EPS for the current year.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data.